COMPUGEN LTDCGENEarnings & Financial Report
Nasdaq · biotechnology
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...
Insider Transactions
Net 90d: −$99.2K · buys $0 / sells $99.2KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-14 | Eran Ophir | President and CEO | Option exercise | 5.0K | $0.83 | $4.1K |
| 2026-04-14 | Eran Ophir | President and CEO | Sell (open market) | 5.0K | $2.90 | $14.5K |
| 2026-04-14 | Zurit Levine | SVP, Business Development | Option exercise | 2.0K | $1.15 | $2.3K |
| 2026-04-14 | Zurit Levine | SVP, Business Development | Sell (open market) | 2.0K | $2.80 | $5.6K |
| 2026-04-10 | Zurit Levine | SVP, Business Development | Option exercise | 1.1K | $0.83 | $933 |
| 2026-04-10 | Zurit Levine | SVP, Business Development | Option exercise | 2.0K | $1.15 | $2.3K |
| 2026-04-10 | Zurit Levine | SVP, Business Development | Sell (open market) | 3.1K | $2.56 | $8.0K |
| 2026-04-10 | Zurit Levine | SVP, Business Development | Option exercise | 1.1K | $0.83 | $933 |
| 2026-04-10 | Zurit Levine | SVP, Business Development | Option exercise | 2.0K | $1.15 | $2.3K |
| 2026-04-10 | Zurit Levine | SVP, Business Development | Sell (open market) | 3.1K | $2.56 | $8.0K |
1–10 of 22
Page 1 / 3